myCAFs are better than yours: targeting myofibroblasts potentiates immunotherapy

Lea Monteran; Neta Erez

doi:10.1016/j.trecan.2022.11.001

myCAFs are better than yours: targeting myofibroblasts potentiates immunotherapy

Lea Monteran, Neta Erez

Pathology

Tel Aviv University

Research output: Contribution to journal › Short survey › peer-review

Abstract

New findings (Krishnamurty et al.) implicate a subset of cancer-associated fibroblasts (CAFs) that express leucine-rich repeat containing 15 (LRRC15) in promoting tumor growth in pancreatic adenocarcinoma (PDAC), by suppressing the antitumor immunity of cytotoxic T cells. Genetic ablation of LRRC15+ CAFs resulted in better response to immune checkpoint blockade, suggesting they may be a novel target for therapy.

Original language	English
Pages (from-to)	1-2
Number of pages	2
Journal	TRENDS IN CANCER
Volume	9
Issue number	1
DOIs	https://doi.org/10.1016/j.trecan.2022.11.001
State	Published - Jan 2023

Keywords

CAFs
LRRC15
PDAC
immune suppression
microenvironment

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.trecan.2022.11.001

Cite this

@article{5e4cdd1e62214fdc8fda2bbb931cc026,

title = "myCAFs are better than yours: targeting myofibroblasts potentiates immunotherapy",

abstract = "New findings (Krishnamurty et al.) implicate a subset of cancer-associated fibroblasts (CAFs) that express leucine-rich repeat containing 15 (LRRC15) in promoting tumor growth in pancreatic adenocarcinoma (PDAC), by suppressing the antitumor immunity of cytotoxic T cells. Genetic ablation of LRRC15+ CAFs resulted in better response to immune checkpoint blockade, suggesting they may be a novel target for therapy.",

keywords = "CAFs, LRRC15, PDAC, immune suppression, microenvironment",

author = "Lea Monteran and Neta Erez",

note = "Publisher Copyright: {\textcopyright} 2022 Elsevier Inc.",

year = "2023",

month = jan,

doi = "10.1016/j.trecan.2022.11.001",

language = "الإنجليزيّة",

volume = "9",

pages = "1--2",

journal = "TRENDS IN CANCER",

issn = "2405-8033",

publisher = "Cell Press",

number = "1",

}

TY - JOUR

T1 - myCAFs are better than yours

T2 - targeting myofibroblasts potentiates immunotherapy

AU - Monteran, Lea

AU - Erez, Neta

PY - 2023/1

Y1 - 2023/1

N2 - New findings (Krishnamurty et al.) implicate a subset of cancer-associated fibroblasts (CAFs) that express leucine-rich repeat containing 15 (LRRC15) in promoting tumor growth in pancreatic adenocarcinoma (PDAC), by suppressing the antitumor immunity of cytotoxic T cells. Genetic ablation of LRRC15+ CAFs resulted in better response to immune checkpoint blockade, suggesting they may be a novel target for therapy.

AB - New findings (Krishnamurty et al.) implicate a subset of cancer-associated fibroblasts (CAFs) that express leucine-rich repeat containing 15 (LRRC15) in promoting tumor growth in pancreatic adenocarcinoma (PDAC), by suppressing the antitumor immunity of cytotoxic T cells. Genetic ablation of LRRC15+ CAFs resulted in better response to immune checkpoint blockade, suggesting they may be a novel target for therapy.

KW - CAFs

KW - LRRC15

KW - PDAC

KW - immune suppression

KW - microenvironment

UR - http://www.scopus.com/inward/record.url?scp=85141515287&partnerID=8YFLogxK

U2 - 10.1016/j.trecan.2022.11.001

DO - 10.1016/j.trecan.2022.11.001

M3 - عرض مختصر

C2 - 36371342

SN - 2405-8033

VL - 9

SP - 1

EP - 2

JO - TRENDS IN CANCER

JF - TRENDS IN CANCER

IS - 1

ER -

myCAFs are better than yours: targeting myofibroblasts potentiates immunotherapy

Abstract

Keywords

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this